X0206 3 2018-06-20 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001744027 PRESTRELSKI STEVEN C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 Chief Scientific Officer Common Stock 451961 D Stock Option (Right to Buy) 0.69 2022-02-23 Common Stock 11228 D Stock Option (Right to Buy) 1.19 2023-12-26 Common Stock 15720 D Stock Option (Right to Buy) 1.55 2027-02-04 Common Stock 28072 D Stock Option (Right to Buy) 1.55 2027-06-12 Common Stock 11266 D Stock Option (Right to Buy) 5.93 2028-01-31 Common Stock 14036 D Series A Preferred Stock Common Stock 30233 D Series B Preferred Stock Common Stock 7130 D 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Each share of preferred stock is convertible on a 1.78112-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date. 13,760 of these shares are held by Steven Prestrelski , and 16,473 of these shares are held by Steven Prestrelski and Tracy Yeo. These shares are held by Steven Prestrelski and Tracy Yeo. Exhibit 24 - Power of Attorney /s/ Barry Deutsch, as Attorney-in-Fact 2018-06-20